Home About company history achievements our team Products Research Markets Contact News	ProCertus has achieved the following corporate and product development milestones: Research and Development Clinical investigators supported by ProCertus are performing a series of five Phase I and Phase I/II clinical studies designed to demonstrate the safety and efficacy of the DermX, ProDermaCel™ and OralX product formulations in normal subjects and cancer patients. May, 2008 - First Phase I study is completed. Normal subjects receiving six week topical application of DermX formulation demonstrated: i) no significant topical or systemic toxicities over the six week drug course at any of the scheduled doses, ii) successful compliance with the topical drug application schedule that involved five applications per week x six weeks, and iii) successful induction of the scored skin endpoint that predicted complete radioprotection in animal models of radiodermatitis. June, 2009 - Dr. James Cleary and Dr. Deepak Khuntia at the University of Wisconsin Carbone Cancer Center begin patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in radiodermatitis prevention of topically applied vasoconstrictor in patients receiving radiotherapy to treat bone metastases. March, 2010 - Dr. Deepak Khuntia and Dr. James Cleary at the University of Wisconsin Carbone Cancer Center open patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in oral mucositis prevention of topically applied vasoconstrictor in patients receiving radiotherapy for head and neck cancer. Completed proof of concept studies in animal models for its lead candidates for DermX, ProDermaCel™ and OralX. Developed and optimized proprietary topical delivery formulations for ProDermaCel™, DermX and OralX. U.S. patent 7,314,959 issued. New family of aminothiols protects against the lethal effects of whole body irradiation; ProCertus is pursuing military and homeland security applications for this family of compounds. Pending patent applications to protect the commercial use of its ProDermaCel™, DermX and OralX products. Funding Raised $2.1 million in an April 2009 round of equity financing led by Venture Investors and Novartis Venture Fund. Received $2.3 million in a March 2007 round of equity financing led by Venture Investors. Novartis Venture Fund and the Wisconsin Alumni Research Foundation also participated in this and previous rounds of equity financing. Received a $1.3 million Phase II SBIR grant from the National Cancer Institute and two Phase I Small Business Innovation Research (SBIR) grants from the National Institutes of Health. Received three rounds of loans and grants from the Wisconsin Department of Commerce totaling $550,000. Raised approximately $8.0 million in total funding to date. Management/Advisors Established a management team to lead the Company through the pharmaceutical product development and corporate partnering phases of the Company's life cycle. Established a Board of Directors with members who have extensive experience in pharmaceutical development. Established a Scientific Advisory Board comprised of experts in oncology and pharmaceutical product development. Patents/Trademarks Obtained exclusive worldwide licenses to those patents that cover the ProCertus product portfolio. Patents represent a technology partnership with Wisconsin Alumni Research Foundation (www.WARF.org). U.S. Patent 7,314,959, “Aminothiol Compounds and Compositions for Use in Conjunction with Cancer Therapy,” issued in January, 2008. Registered trademarks for "ProCertus BioPharm©" and "Technologies that Protect©."